Replies to post #373260 on Amarin Corp Plc (AMRN)

[oneragman]

Raf, total failure by management! Not surprising the worst performing stock I own today. Guessing I would say the only reason we are up is because what is happening in the US should force their hand to sell. There are plenty of deals in biotech today. Give me $15 right now and I will double that this year in another company. Of course they will piss away 2 years and when biotech is at a high and sell for that.

[Number sleven]

Raf, Thanks for the numbers.
Sleven,

[hayward]

rafunrafun

What in the world so 600 employees due all day ???

Michael

[rafunrafun]

Scripts for week ending March 18, 2022

Drug Industry TRx: -1.7% w/w

Vascepa
TRx 72,976; +2.8% (+1,976) w/w; -13.2% y/y
NRx 33,638; +1.3% (+416) w/w; -15.5% y/y
Ref 39,338; +4.1% (+1,560) w/w; -11.3% y/y

Lovaza (Generic & Brand)
TRx 63,372; -0.2% (-107) w/w; -0.1% y/y
NRx 33,089; -0.4% (-144) w/w; +3.7% y/y
Ref 30,283; -0.1% (+38) w/w; -4.0% y/y

Generic Vascepa
TRx 30,653; +0.1% (+44) w/w; As % of total V: 29.6%
NRx 17,076; -2.8% (-489) w/w; As % of total V: 33.7%
Ref 13,577; +4.1% (+534) w/w; As % of total V: 25.7%

Generic Vascepa by Manufacturer
Hikma - TRx 7,540 (-145); Generic share 24.6%; Total V share 7.3%
Reddy - TRx 14,111 (-208); Generic share 46.0%; Total V share 13.6%
Apotex - TRx 9,002 (+396); Generic share 29.4%; Total V share 8.7%

Vascepa + Generic Vascepa
TRx 103,629; +2.0% (+2,020) w/w; +10.4% y/y
NRx 50,714; -0.1% (-74) w/w; +11.2% y/y
Ref 52,915; +4.1% (+2,094) w/w; +9.6% y/y